Immunostimulatory functions of adoptively transferred MDSCs in experimental blunt chest trauma.
Adaptive Immunity
/ immunology
Animals
Apoptosis
/ immunology
Bronchoalveolar Lavage
Cell Proliferation
/ genetics
Disease Models, Animal
Humans
Immunity, Innate
/ immunology
Inflammation
/ immunology
Leukocytes
/ immunology
Liver
/ immunology
Lung
/ immunology
Lymphocyte Activation
/ immunology
Mice
Myeloid-Derived Suppressor Cells
/ immunology
Spleen
/ immunology
T-Lymphocytes
/ immunology
Th1 Cells
/ immunology
Thoracic Injuries
/ immunology
Wounds, Nonpenetrating
/ immunology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 05 2019
29 05 2019
Historique:
received:
18
02
2019
accepted:
14
05
2019
entrez:
31
5
2019
pubmed:
31
5
2019
medline:
21
10
2020
Statut:
epublish
Résumé
Myeloid-derived suppressor cells (MDSCs) expand during inflammation and exhibit immunomodulatory functions on innate and adaptive immunity. However, their impact on trauma-induced immune responses, characterized by an early pro-inflammatory phase and dysregulated adaptive immunity involving lymphocyte apoptosis, exhaustion and unresponsiveness is less clear. Therefore, we adoptively transferred in vitro-generated MDSCs shortly before experimental blunt chest trauma (TxT). MDSCs preferentially homed into spleen and liver, but were undetectable in the injured lung, although pro-inflammatory mediators transiently increased in the bronchoalveolar lavage (BAL). Surprisingly, MDSC treatment strongly increased splenocyte numbers, however, without altering the percentage of splenic leukocyte populations. T cells of MDSC-treated TxT mice exhibited an activated phenotype characterized by expression of activation markers and elevated proliferative capacity in vitro, which was not accompanied by up-regulated exhaustion markers or unresponsiveness towards in vitro activation. Most importantly, also T cell expansion after staphylococcal enterotoxin B (SEB) stimulation in vivo was unchanged between MDSC-treated or untreated mice. After MDSC transfer, T cells preferentially exhibited a Th1 phenotype, a prerequisite to circumvent post-traumatic infectious complications. Our findings reveal a totally unexpected immunostimulatory role of adoptively transferred MDSCs in TxT and might offer options to interfere with post-traumatic malfunction of the adaptive immune response.
Identifiants
pubmed: 31142770
doi: 10.1038/s41598-019-44419-5
pii: 10.1038/s41598-019-44419-5
pmc: PMC6541619
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7992Références
Cancer Immunol Immunother. 2011 Oct;60(10):1419-30
pubmed: 21644036
J Immunol. 2010 Jun 1;184(11):6151-60
pubmed: 20427766
J Neuroimmunol. 2016 Jan 15;290:96-102
pubmed: 26711577
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
J Immunol. 2007 Jul 15;179(2):977-83
pubmed: 17617589
Eur J Immunol. 2005 Dec;35(12):3533-44
pubmed: 16331707
Sci Rep. 2017 Oct 9;7(1):12808
pubmed: 28993671
PLoS One. 2014 Jun 13;9(6):e100013
pubmed: 24927018
Hum Immunol. 2017 Feb;78(2):113-119
pubmed: 27939507
Oncotarget. 2016 Apr 5;7(14):17565-78
pubmed: 27007050
J Exp Med. 2007 Jun 11;204(6):1463-74
pubmed: 17548519
Scand J Immunol. 2014 Feb;79(2):98-104
pubmed: 24313384
Eur J Immunol. 2009 Dec;39(12):3538-51
pubmed: 19830733
J Mol Med (Berl). 2016 Aug;94(8):911-20
pubmed: 26936474
Exp Neurol. 2016 Dec;286:50-60
pubmed: 27693617
J Immunol. 2018 Jan 15;200(2):422-431
pubmed: 29311384
J Trauma. 2007 Dec;63(6):1407-17
pubmed: 18212667
Immunity. 2010 Jun 25;32(6):790-802
pubmed: 20605485
J Immunol. 2006 Feb 15;176(4):2085-94
pubmed: 16455964
Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):1074-8
pubmed: 1899481
J Immunol. 2013 Aug 1;191(3):1073-81
pubmed: 23804709
Exp Neurol. 2010 Nov;226(1):242-53
pubmed: 20832407
Bone. 2016 Dec;93:113-124
pubmed: 27664567
Mediators Inflamm. 2015;2015:458626
pubmed: 25709155
Autoimmunity. 2017 May;50(3):170-181
pubmed: 28276713
Mucosal Immunol. 2010 Nov;3(6):578-93
pubmed: 20664577
Front Immunol. 2018 Feb 15;9:282
pubmed: 29497426
Ann Surg. 1995 Oct;222(4):482-90; discussion 490-2
pubmed: 7574928
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Eur Rev Med Pharmacol Sci. 2015 Nov;19(21):4171-81
pubmed: 26592844
Blood. 2013 Mar 7;121(10):1740-8
pubmed: 23305737
Blood. 2015 Aug 27;126(9):1138-48
pubmed: 26185131
Infect Immun. 2012 Jun;80(6):2026-34
pubmed: 22451518
J Leukoc Biol. 2017 Sep;102(3):727-740
pubmed: 28546500
J Neurochem. 2013 Apr;125(1):74-88
pubmed: 23278273
J Immunol. 2016 Feb 1;196(3):1132-45
pubmed: 26712947
Nat Immunol. 2018 Apr;19(4):327-341
pubmed: 29507356
PLoS One. 2011;6(9):e25242
pubmed: 21966467
Circulation. 2018 Jul 10;138(2):181-197
pubmed: 29437117
Cytokine. 2016 Dec;88:214-221
pubmed: 27676155
Oncoimmunology. 2015 Oct 14;5(2):e1004983
pubmed: 27057424
Clin Transl Immunology. 2016 Apr 29;5(4):e77
pubmed: 27195120
Clin Sci (Lond). 2016 Aug 1;130(16):1453-67
pubmed: 27231253
J Leukoc Biol. 2012 Dec;92(6):1199-206
pubmed: 23077247
Arthritis Rheumatol. 2016 Nov;68(11):2717-2727
pubmed: 27214349
J Leukoc Biol. 2014 Nov;96(5):675-84
pubmed: 24948701
Sci Rep. 2016 Mar 04;6:22658
pubmed: 26939768
Trends Immunol. 2011 Jan;32(1):19-25
pubmed: 21067974
Oncol Lett. 2017 Aug;14(2):1766-1774
pubmed: 28789407